Hemophilia is one of the best researched monogenic diseases. Hemophilia A will affect approximately 1:5,000 male live births. In recent decades, great progress has been made with the introduction of recombinant proteins in the 1990s for therapy and prophylaxis, securing adequate availability and, with the introduction of the prophylaxis concept, reducing the negative impact of hemophilia on morbidity (especially arthropathy). Despite this progress, there are still challenges to overcome to secure adequate prophylaxis and treatment: for the time being, causal pharmacological hemophilia prophylaxis and therapy requires repeated i.v. application on a regular basis. Although this approach leads to a reduced comorbidity, it does not yet represent an optimized approach with continuous reversal of the hemophilic defect, which would be the ideal solution. This review summarizes the very new treatment strategies for the treatment of hemophilia A and B.

Keywords:
Antibodies, Factor VIII, Gene transfer, Hemophilia, Emicizumab, Concizumab, Gene therapy
1.
Sandset PM: Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996;26(suppl 4):154-165.
2.
Broze GJ Jr, Girard TJ: Tissue factor pathway inhibitor: structure-function. Front Biosci 2012;17:262-280.
3.
Peterson JA, Maroney SA, Mast AE: Targeting TFPI for hemophilia treatment. Thromb Res 2016;141(suppl 2): S28-30.
4.
Maroney SA, Mast AE: New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost 2015;13(suppl 1):S200-207.
5.
Piro O, Broze GJ Jr: Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation 2004;110:3567-3572.
6.
Yang Y, He X, Li J, He S: Effect of monoclonal antibody against human tissue factor pathway inhibitor on plasma coagulation time (in Chinese). Hunan Yi Ke Da Xue Xue Bao 1997;22:297-300.
7.
Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O: Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995;6:388-394.
8.
Prasad S, Lillicrap D, Labelle A, Knappe S, Keller T, Burnett E, Powell S, Johnson KW: Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008;111:672-679.
9.
Gorczyca ME, Nair SC, Jilma B, Priya S, Male C, Reitter S, Knoebl P, Gilbert JC, Schaub RG, Dockal M, McGinness KE, Pabinger I, Srivastava A: Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost 2012;10:1581-1590.
10.
Hilden I, Lauritzen B, Sorensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjorn SE: Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012;119:5871-5878.
11.
Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Nielsen LV, Johansen PB, Hermit MB, Petersen LC, Mast AE: Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci U S A 2012;109:3927-3931.
12.
Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE: Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011;117:5514-5522.
13.
Parunov LA, Fadeeva OA, Balandina AN, Soshitova NP, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA: Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 2011;9:1825-1834.
14.
Petersen LC: Hemostatic properties of a TFPI antibody. Thromb Res 2012;129(suppl 2):S44-45.
15.
Waters EK, Genga RM, Thomson HA, Kurz JC, Schaub RG, Scheiflinger F, McGinness KE: Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost 2013;11:1137-1145.
16.
Chang JY, Chantrathammachart P, Monroe DM, Key NS: Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb Res 2012;130:e151-157.
17.
Gissel M, Orfeo T, Foley JH, Butenas S: Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 2012;130:948-955.
18.
Willyard C: Thrombosis: balancing act. Nature 2014;515:S168-169.
19.
Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB: Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia 2017;23:769-776.
20.
Gu JM, Patel C, Kauser K: Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B. Blood 2015;126:4672.
21.
Gu JM, Zhao XY, Schwarz T, Schuhmacher J, Baumann A, Ho E, Subramanyan B, Tran K, Myles T, Patel C, Koellnberger M: Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in Cynomolgus monkeys. AAPS J 2017;19:1186-1195.
22.
Agerso H, Overgaard RV, Petersen MB, Hansen L, Hermit MB, Sorensen MH, Petersen LC, Hilden I: Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci 2014;56:65-69.
23.
Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, Klamroth R, Knoebl P, Laffan M, Mahlangu J, Miesbach W, Dalsgaard Nielsen J, Martin-Salces M, Angchaisuksiri P: Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015;13:743-754.
24.
Paz P, Xie J, Aswad F: Antibody engineering of anti-TFPI bypass therapeutic BAY 1093884:isotype selection and sequence optimization. Blood 2015;126:3496.
25.
Rakhe S, Hett SP, Murphy JE, Pittman DD: An antibody to tissue factor pathway inhibitor (PF-06741086) in combination with recombinant factor VIIa increases hemostasis in hemophilia plasma without excessive thrombin generation. Blood 2016;128:2566-2566.
26.
Jasuja R, Barakat A, Murphy JE, Pittman DD: An antibody to tissue factor pathway inhibitor (TFPI) restores hemostasis after the onset of bleeding in hemophilic a mouse injury models. Blood 2016;128:3761-3761.
27.
Ogiwara K, Nogami K, Matsumoto T, Shima M: Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor. Int J Hematol 2014;99:577-587.
28.
Varadi K, Tangada S, Loeschberger M, Montsch P, Schrenk G, Ewenstein B, Turecek PL: Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. Haemophilia 2016;22:615-624.
29.
Safdar H, Cheung KL, Vos HL, Gonzalez FJ, Reitsma PH, Inoue Y, van Vlijmen BJ: Modulation of mouse coagulation gene transcription following acute in vivo delivery of synthetic small interfering RNAs targeting HNF4alpha and C/EBPalpha. PloS One 2012;7:e38104.
30.
Safdar H, Cheung KL, Salvatori D, Versteeg HH, Laghmani el H, Wagenaar GT, Reitsma PH, van Vlijmen BJ: Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production. Blood 2013;121:4413-4416.
31.
Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, Prabhala H, Zhang X, Attarwala H, Hutabarat R, Foster D, Milstein S, Charisse K, Kuchimanchi S, Maier MA, Nechev L, Kandasamy P, Kel'in AV, Nair JK, Rajeev KG, Manoharan M, Meyers R, Sorensen B, Simon AR, Dargaud Y, Negrier C, Camire RM, Akinc A: An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015;21:492-497.
32.
Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I, Kazmi R, Chowdary P, Gercheva-Kyuchukova L, Mamonov V, Timofeeva M, Soh CH, Garg P, Vaishnaw A, Akinc A, Sorensen B, Ragni MV: Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017;377:819-828.
33.
World Federation of Hemophilia: Alnylam suspends fitusiran dosing due to thrombotic event in phase 2 open-label extension study. 2017. https://news.wfh.org/alnylam-suspends-fitusiran-dosing-due-thrombotic-event-phase-2-open-label-extension-study/ (last accessed March 6, 2018).
34.
World Federation of Hemophilia: Update: FDA lifts suspension of fitusiran trial. 2017. https://news.wfh.org/update-fda-lifts-suspension-fitusiran-trial/ (last accessed March 6, 2018).
35.
Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C, Tanaka E, Kikuchi Y, Wakabayashi T, Wada M, Goto M, Toyoda T, Ueyama A, Suzuki S, Haraya K, Tachibana T, Kawabe Y, Shima M, Yoshioka A, Hattori K: A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012;18:1570-1574.
36.
Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, Yoshihashi K, Harada A, Funaki M, Haraya K, Tachibana T, Suzuki S, Esaki K, Nabuchi Y, Hattori K: Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PloS One 2013;8:e57479.
37.
Sampei Z, Igawa T, Soeda T, Funaki M, Yoshihashi K, Kitazawa T, Muto A, Kojima T, Nakamura S, Hattori K: Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. mAbs 2015;7:120-128.
38.
Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, Shima M: A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016;127:1633-1641.
39.
Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, Sampei Z, Kuramochi T, Sakamoto A, Haraya K, Adachi K, Kawabe Y, Nogami K, Shima M, Hattori K: Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014;124:3165-3171.
40.
Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K: Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016;374:2044-2053.
41.
Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Kasai R, Yoneyama K, Yoshida H, Nogami K: Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 2017;1:1891-1899.
42.
Jimenez-Yuste V, Shima M, Fukutake K, Lehle M, Chebon S, Retout S, Portron A, Levy GG: Emicizumab Subcutaneous Dosing every 4 weeks for the management of hemophilia a: preliminary data from the pharmacokinetic run-in cohort of a multicenter, open-label, phase 3 study (HAVEN 4). Blood 2017;130:86-86.
43.
U.S. Food and drug Administration: FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. 2017. www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585650.htm (last accessed March 6, 2018).
44.
Scott LJ, Kim ES: Emicizumab-kxwh: first global approval. Drugs 2018;78:269-274.
45.
Chuah MK, Nair N, VandenDriessche T: Recent progress in gene therapy for hemophilia. Hum Gene Ther 2012;23:557-565.
46.
Petrus I, Chuah M, VandenDriessche T: Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med 2010;12:797-809.
47.
Vandendriessche T, Chuah MK: Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B. Hum Gene Ther 2012;23:4-6.
48.
Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, Pasi KJ: AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017;377:2519-2530.
49.
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA: Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 2017;377:2215-2227.
© 2018 S. Karger GmbH, Freiburg
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.